ストックスクリーナーアプリを入手
6.18
0.16%
-0.01
アフターアワーズ：
6.18
Myriad Genetics Inc (MYGN) 最新ニュース
ETFs Investing in Myriad Genetics, Inc. Stocks - TradingView
Is This the Right Time to Hold MYGN Stock in Your Portfolio? - Yahoo Finance Singapore
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh - qz.com
BofA Securities Maintains Myriad Genetics(MYGN.US) With Sell Rating, Announces Target Price $4 - Moomoo
Myriad Genetics (MYGN) Q4 2024 earnings summary - Quartr
Myriad Genetics (MYGN) Proxy filing Summary - Quartr
(MYGN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Myriad Genetics (MYGN) Surges 3.5%: Approaching Resistance at $6.51ADD Alert - dars.gov.et
Myriad Genetics Q1 2026 Earnings: EPS Miss Clouds Diagnostic Growth OutlookGross Profit Margin - dars.gov.et
Meta-analysis confirms Myriad's Prolaris test e... - Pluang
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad's Prolaris Biopsy Test in Localized Prostate Cancer - 富途牛牛
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer - Yahoo Finance
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS - BioSpace
Sera Prognostics adds former Myriad Genetics CEO to board By Investing.com - Investing.com South Africa
MYGNMyriad Genetics Inc Latest SEC Filings - Finviz
Sera Prognostics adds former Myriad Genetics CEO to board - Investing.com
Sera Prognostics adds former Myriad CEO Mark Capone to board - Stock Titan
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 - Yahoo Finance
Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock? - Yahoo Finance
(MYGN) Risk Channels and Responsive Allocation - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Price to sales forward of Myriad Genetics, Inc. – NASDAQ:MYGN - TradingView
Price to book forward of Myriad Genetics, Inc. – NASDAQ:MYGN - TradingView
Myriad Genetics, Inc. Actuals & Estimates (NASDAQ:MYGN) - TradingView
897518 Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Myriad Genetics, Inc. – LS:897518 - TradingView
Price to sales forward of Myriad Genetics, Inc. – LS:897518 - TradingView
Enterprise value to revenue forward of Myriad Genetics, Inc. – NASDAQ:MYGN - TradingView
Enterprise value to revenue forward of Myriad Genetics, Inc. – LS:897518 - TradingView
MYGN Stock Price, Quote & Chart - ChartMill
MYGN Forecast — Price Target — Prediction for 2027 - TradingView
Myriad Genetics, Inc. Actuals & Estimates (FWB:MYD) - TradingView
Myriad Genetics clears analyst hurdle, shares steady on NASDAQ - ad-hoc-news.de
MYD Forecast — Price Target — Prediction for 2027 - TradingView
Why Is Myriad Genetics (MYGN) Stock Rocketing Higher Today - Yahoo Finance
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication - Sahm
Director at Myriad Genetics (MYGN) reports 195,507-share Common Stock stake - Stock Titan
Myriad Genetics expands cancer detection test availability By Investing.com - Investing.com Australia
Form 8K Myriad Genetics Inc For: 23 June By Investing.com - Investing.com Australia
MYGN PE Ratio & Valuation, Is MYGN Overvalued - Intellectia AI
Myriad Genetics expands cancer detection test availability - Investing.com
Myriad Genetics director Daniel Skovronsky resigns from board By Investing.com - Investing.com Australia
Myriad Genetics director Daniel Skovronsky resigns from board - Investing.com UK
MYRIAD GENETICS, INC. 8-K Filing: Key Company Information and SEC Compliance Details for June 2026 - Minichart
Myriad widens cancer test access as breast study bolsters its case - Stock Titan
0.61%
1.88%
大文字化:
|
ボリューム (24 時間):